BASF (Ludwigshafen, Germany) has acquired Equateq Ltd., a manufacturer of concentrated omega-3 fatty acids using proprietary chromatographic separation methods. Equateq, which has a production site located on the Isle of Lewis in Scotland with 47 employees, will be integrated into the Pharma Ingredients & Services unit, which is part of BASF’s Nutrition & Health division.
Financial details were not disclosed. “Equateq’s technologies will enable us to customize fatty acid concentrates with variable ratios of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) at concentration levels of up to 99 percent purity. This is unique in the market,” said Martin Widmann, senior vice president of BASF’s Pharma Ingredients & Services. BASF is an NCN Cornerstone Investor.
Disclaimer: NCN does not warrant the accuracy, reliability, or timeliness of any NCN news item. Before relying on any NCN News item the information should be independently verified.
For more finance and investment information, visit Nutrition Capital Network news.